The Under Armour, Inc. Third Amended and Restated 2005 Omnibus Long-Term Incentive Plan as amended (the "2005 Plan") provides for the issuance of stock options, restricted stock, restricted stock units and other equity awards to officers, directors, key employees and other persons. The 2005 Plan terminates in 2025. As of March 31, 2022, 8.3 million Class A shares and 25.7 million Class C shares are available for future grants of awards under the 2005 Plan.

Total stock-based compensation expense associated with awards granted to employees and non-employee directors for the three months ended March 31, 2022 and 2021 was $11.8 million and $10.4 million, respectively. As of March 31, 2022, the Company had $108.4 million of unrecognized compensation expense related to these awards expected to be recognized over a weighted average period of 2.63 years. Refer to "Stock Options" and "Restricted Stock and Restricted Stock Unit Awards" below for further information on these awards.

Stock options, restricted stock and restricted stock unit awards under the 2005 Plan generally vest ratably over a two to five years period. The contractual term for stock options is generally 10 years from the date of grant. The Company generally receives a tax deduction for any ordinary income recognized by a participant in respect to an award under the 2005 Plan.

The Company's Non-Employee Director Compensation Plan (the "Director Compensation Plan") provides for cash compensation and equity awards to non-employee directors of the Company under the 2005 Plan. Non-employee directors have the option to defer the value of their annual cash retainers as deferred stock units in accordance with the Under Armour, Inc. Non-Employee Deferred Stock Unit Plan (the "DSU Plan"). Each new non-

employee director receives an award of restricted stock units upon the initial election to the Board of Directors, with the units covering stock valued at $100 thousand on the grant date and vesting in three equal annual installments. In addition, each non-employee director receives, following each annual stockholders' meeting, a grant under the 2005 Plan of restricted stock units covering stock valued at $150 thousand on the grant date. Each award vests 100% on the date of the next annual stockholders' meeting following the grant date.

The receipt of the shares otherwise deliverable upon vesting of the restricted stock units automatically defers into deferred stock units under the DSU Plan. Under the DSU Plan each deferred stock unit represents the Company’s obligation to issue one share of the Company's Class A or Class C Common Stock with the shares delivered six months following the termination of the director's service. The Company had 0.7 million deferred stock units outstanding as of March 31, 2022.

The Company's Employee Stock Purchase Plan (the "ESPP") allows for the purchase of Class A Common Stock and Class C Common Stock by all eligible employees at a 15% discount from fair market value subject to certain limits as defined in the ESPP. As of March 31, 2022, 2.7 million Class A shares and 1.7 million Class C shares are available for future purchases under the ESPP. During the three months ended March 31, 2022 and 2021, 69.8 thousand and 59.0 thousand Class C shares were purchased under the ESPP, respectively.

In addition to the plans discussed above, the Company may also, from time to time, issue deferred stock units or restricted stock units to certain of our marketing partners in connection with their entering into endorsement and other marketing services agreements with us. The terms of each agreement set forth the number of units to be granted and the delivery dates for the shares, which range over a multi-year period, depending on the contract.

Total stock-based compensation expense related to these awards for the three months ended March 31, 2022 and 2021 was $0.8 million and $0.9 million, respectively. As of March 31, 2022, we had $7.7 million of unrecognized compensation expense associated with these awards expected to be recognized over a weighted average period of 2.51 years.

No stock options were granted during the three months ended March 31, 2022 and 2021. A summary of the Company's stock options activity for the three months ended March 31, 2022 is presented below:


	Number of Stock Options	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)	Total Intrinsic Value
Outstanding at December 31,2021	1,578	$	19.44	6.07	$	2,403
Granted, at fair market value	—	—
Exercised	—	—
Forfeited	—	—
Outstanding at March 31, 2022	1,578	$	19.44	5.82	$	217
Options exercisable at March 31, 2022	1,369	$	19.92	5.56	$	152

A summary of the Company's restricted stock and restricted stock unit awards activity for the three months ended March 31, 2022 is presented below: